pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
PTC:VS-TC
Phase 1 · other · Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
PTC:VS-TC for Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies. is a Phase 1 program (other) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Internal code PTC:VS-TC
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Istituto Gentili S.r.l.
- Phase
- Phase 1
- Modality
- other
- Indication
- Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
- Status
- active
- Trials
- 1